# LENZ Therapeutics, Inc.: overview

LENZ · Nasdaq · CIK 1815776 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lenz.md) · [Financials](/companies/lenz/financials.md) · [Filings](/companies/lenz/filings.md) · [Insiders](/companies/lenz/insiders.md)

Latest reported revenue: [$5.5m](/filings/0001815776-26-000052.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001815776-26-000052).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001815776-25-000071.md) | [0.0 d](/filings/0001815776-26-000011.md) | [0.0](/filings/0001815776-26-000037.md) | [5.0](/filings/0001815776-26-000052.md) | [12.5](/filings/0001815776-25-000071.md) | [1.6 d](/filings/0001815776-26-000011.md) | [1.9](/filings/0001815776-26-000037.md) | [5.5](/filings/0001815776-26-000052.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | [(337.1%)](/filings/0001815776-26-000052.md) | [(151.1%)](/filings/0001815776-25-000071.md) | [(2422.1%) d](/filings/0001815776-26-000011.md) | [(2321.7%)](/filings/0001815776-26-000037.md) | [(622.9%)](/filings/0001815776-26-000052.md) |
| Net margin | % | not reported | not reported | not reported | [(298.2%)](/filings/0001815776-26-000052.md) | [(133.6%)](/filings/0001815776-25-000071.md) | [(2260.5%) d](/filings/0001815776-26-000011.md) | [(2182.4%)](/filings/0001815776-26-000052.md) | [(581.8%)](/filings/0001815776-26-000052.md) |
| Diluted EPS | $ per share | [(0.38)](/filings/0001815776-25-000071.md) | not reported | [(0.53)](/filings/0001815776-26-000037.md) | [(0.53)](/filings/0001815776-26-000052.md) | [(0.59)](/filings/0001815776-25-000071.md) | not reported | [(1.32)](/filings/0001815776-26-000037.md) | [(1.02)](/filings/0001815776-26-000052.md) |
| Free cash flow | $m | [(10.8) d](/filings/0001815776-25-000071.md) | [(9.2) d](/filings/0001815776-26-000011.md) | [(16.2)](/filings/0001815776-26-000037.md) | [(11.7) d](/filings/0001815776-26-000052.md) | [(9.0) d](/filings/0001815776-25-000071.md) | [(33.1) d](/filings/0001815776-26-000011.md) | [(33.6)](/filings/0001815776-26-000037.md) | [(38.7) d](/filings/0001815776-26-000052.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [0.0](/filings/0001815776-26-000011.md) | [19.1](/filings/0001815776-26-000011.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | [(477.5%)](/filings/0001815776-26-000011.md) |
| Net margin | % | not reported | not reported | not reported | not reported | [(430.3%)](/filings/0001815776-26-000011.md) |
| Diluted EPS | $ per share | [(2.45)](/filings/0000950170-23-008764.md) | [(1.84)](/filings/0000950170-24-021135.md) | [(35.71)](/filings/0001815776-25-000019.md) | [(2.34)](/filings/0001815776-26-000011.md) | [(2.85)](/filings/0001815776-26-000011.md) |
| Free cash flow | $m | [(58.6)](/filings/0000950170-23-008764.md) | [(94.6)](/filings/0000950170-24-021135.md) | [(60.4)](/filings/0001815776-25-000019.md) | [(59.9)](/filings/0001815776-26-000011.md) | [(70.0)](/filings/0001815776-26-000011.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lenz/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $23.7m | 4,178,823 |  | Unchanged |
| [Alpha Wave Global, LP](/funds/1558858.md) | 2026-06-30 | $20.5m | 3,612,211 |  | Unchanged |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $20.2m | 3,558,905 |  | Reduced −38,879 |
| [Versant Venture Management, LLC](/funds/1560009.md) | 2026-06-30 | $15.1m | 2,656,888 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $13.0m | 2,292,121 |  | Added +315,298 |
| [Squarepoint Ops LLC](/funds/1642575.md) | 2026-06-30 | $9.9m | 1,747,096 |  | Added +240,597 |
| [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $8.8m | 1,547,883 |  | Added +391,722 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $8.6m | 1,508,478 |  | Added +639,221 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.2m | 1,097,755 |  | Added +56,567 |
| [72 Investment Holdings, LLC](/funds/1832749.md) | 2026-06-30 | $5.8m | 1,017,751 |  | Unchanged |

## Recent filings

[All 348 filings](/companies/lenz/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-11 | 20:13 ET | [10-Q](/filings/0001815776-26-000052.md) | Quarterly report, period 2026-06-30 | 0001815776-26-000052 |
| 2026-08-11 | 20:08 ET | [8-K](/filings/0001815776-26-000051.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001815776-26-000051 |
| 2026-07-02 | 21:00 ET | [8-K](/filings/0001815776-26-000046.md) | 5.02 Departure or appointment of officers or directors | 0001815776-26-000046 |
| 2026-06-12 | 20:08 ET | [8-K](/filings/0001815776-26-000041.md) | 5.07 Shareholder vote results | 0001815776-26-000041 |
| 2026-05-11 | 20:10 ET | [10-Q](/filings/0001815776-26-000037.md) | Quarterly report, period 2026-03-31 | 0001815776-26-000037 |
| 2026-05-11 | 20:07 ET | [8-K](/filings/0001815776-26-000035.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001815776-26-000035 |
| 2026-04-28 | 20:39 ET | [DEF 14A](/filings/0001815776-26-000026.md) | Proxy statement, period 2026-06-12 | 0001815776-26-000026 |
| 2026-03-24 | 20:10 ET | [10-K](/filings/0001815776-26-000011.md) | Annual report, period 2025-12-31 | 0001815776-26-000011 |
| 2026-03-24 | 12:10 ET | [8-K](/filings/0001815776-26-000008.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001815776-26-000008 |
| 2026-01-07 | 22:10 ET | [8-K](/filings/0001815776-26-000003.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001815776-26-000003 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001815776-26-000011.md), filed Mar 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/33daf699-7577-43a6-9cdd-3c7e6ee3ffe8)

## About the filer

- CIK: 1815776
- Tickers: LENZ
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.